Galecto, Inc. announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich spent 12 years with Novartis in roles of increasing responsibility, including assistant to the Chairman and CEO, regional sales and marketing manager and disease area leader for myeloma in Europe. She joined Roche in 2015 as international business leader of the cancer treatment Avastin.

From 2017 to 2020, she served as Head of BRIDGEs Partnering North America & Asia at Evotec, leading collaborations with universities and financing partners.